LSD shows early promise as a potential anxiety treatment | AI News Digest
A recent study published in JAMA indicates that LSD, specifically in the form of MM120, shows promise as a treatment for generalized anxiety disorder (GAD). Conducted with 198 adults across 22 U.S. sites, the trial found that a single dose significantly reduced anxiety symptoms, with effects lasting up to three months. Experts highlight the study's rigorous design and the potential for LSD to offer a new alternative to daily anxiety medications. However, caution is advised as further research is needed to confirm these findings and assess safety in broader populations. The study marks a shift in attitudes towards LSD, once viewed solely as a hallucinogen, now being explored for its medical benefits.
